The reduced nuclear localization of QKI likely diminishes its ability to promote PABPN1 LLPS in cancer cells, as validated by overexpression of QKI and QKI-NLS (Figs. 5C, 5D and S12), and further supported by the effect of arsenite treatment (Fig. 5H and 5I). The gene discussed is PABPN1; the disease is cancer.